91快活林

2024-至今(Date)，91快活林 ，副教授、硕导。

Associate Professor, Master Advisor, College of Chemistry, Fuzhou University.

2019-2024，清华大学清华-伯克利深圳学院，工学博士。

Ph.D., Tsinghua-Berkeley Shenzhen Institute, Tsinghua University.

2015-2019，华中科技大学生命科学与技术学院，理学学士。

B.Sc., College of Life Science and Technology, Huazhong University of Science and Technology.

主要从事生物医学领域研究，简要包括：肿瘤靶向治疗、新型肿瘤治疗靶点挖掘、新型光敏剂开发、肿瘤光动力治疗、光动力抗菌。

Ploughing the field of biomedicine, briefly including: tumor targeted therapy, identification of novel oncotherapeutic targets, development of novel photosensitizer, photodynamic oncotherapy, anti-bacteria photodynamic therapy.

主持项目

91快活林 福建省高校测试中心贵重仪器设备开放测试基金资助项目/Fujian College Association Instrumental Analysis Center of Fuzhou University Testing Fund of Precious Apparatus (Project ID: 2026T026) 2025-2026

91快活林 科研启动经费/the Startup Fund of Fuzhou University (Project ID: 511624) 2025-2027

参与项目

福建省自然科学基金重点项目/Key Project of Natural Science Foundation of Fujian Province (Project ID: 2025J02010) 2025-2028

科技部国家重点研发计划/National Key R&D Program of the Ministry of Science and Technology (Project ID: 2023YFA0913602) 2023-2028

国家自然科学基金面上项目/National Natural Science Foundation of China (Project ID: 82172618) 2022-2025

1.Huang P, Wolde T, Bhardwaj V, Zhang X, and Pandey V. TFF3 and PVRL2 co-targeting identified by multi-omics approach as an effective cancer immunosuppression strategy.Life Sciences. 2024, 357:123113.

2.Huang P, Zhang X, Prabhu JS, and Pandey V. Therapeutic vulnerabilities in triple negative breast cancer: stem-like traits explored within molecular classification.Biomedicine & Pharmacotherapy. 2024, 147:116584.

3.Wolde T, Huang J,Huang P, Pandey V, and Qin PW. Depleted-MLH1 expression predicts prognosis and immunotherapeutic efficacy in uterine corpus endometrial cancer: an in silico approach.BioMedInformatics. 2024, 4:326-346.

4.Zhang X, Wang LQ, Chen S,Huang P, Ma L, Ding H, Basappa B, Zhu T, Lobie PE, and Pandey V. Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma.Communications medicine. 2022, 2:82.

5.Zhang X,Huang P^(co-primary), Wang LQ, Chen S, Basappa B, Zhu T, Lobie PE, and Pandey V. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma.Cell death & disease. 2022, 12:558.